蒯樂天博士：當(dāng)科技普惠，從藥物發(fā)現(xiàn)開始 | 逐夢者說 | Bilingual

編者按：“讓天下沒有難做的藥，難治的病”，是初心，更是愿景。二十五年來，藥明康德步履不停：從一間實驗室，到覆蓋亞洲、歐洲和北美的全球網(wǎng)絡(luò)。從早期的化學(xué)合成服務(wù)，到貫穿研究（R）、開發(fā)（D）和生產(chǎn)（M）的一體化平臺。從第一位客戶，到全球三十多個國家的數(shù)千合作伙伴。不斷發(fā)展的，是規(guī)模與能力；始終堅守的，是夢想與承諾。

致敬來時路，共譜新篇章！在二十五周年之際，我們以“逐夢者”視角，回顧藥明康德成長發(fā)展的崢嶸歲月，回望賦能客戶創(chuàng)新的并肩往事，更以獨特的“藥明精神”展望未來新篇章。

那一天，在藥明康德25周年榮耀盛典的舞臺上，當(dāng)蒯樂天博士走上臺領(lǐng)取“杰出科學(xué)家獎”時，全場響起了熱烈的掌聲。

這份榮譽，不僅是對他科研能力的高度認(rèn)可，更是表彰他和團隊對變革新藥發(fā)現(xiàn)方式所作出的努力和貢獻。

七年前，蒯樂天博士選擇加入了藥明康德。彼時，他希望能夠在這里將原本復(fù)雜、僅限于學(xué)術(shù)實驗室使用的DNA編碼化合物庫（DEL）篩選技術(shù)變?yōu)楫a(chǎn)品，讓每一位科研人員都能便捷使用。這樣一個極具遠見的想法，在藥明康德這樣為全行業(yè)賦能的平臺上似乎更容易實現(xiàn)。

“我們是從零開始的，”他回憶道，“盡管當(dāng)時的能力和體系還不夠完善，但大家還是對DEL產(chǎn)品的未來充滿信心——我們相信一定能打造出改變藥物研發(fā)格局的技術(shù)產(chǎn)品。”

如今，這一信念已轉(zhuǎn)變成了現(xiàn)實。DEL已成為藥明康德生物學(xué)平臺（WuXi Biology）發(fā)展最為迅速的核心技術(shù)之一，每年為客戶篩選數(shù)十億級別的化合物，為全球成千上萬的創(chuàng)新者賦能。

當(dāng)晚站在聚光燈下，蒯樂天博士回望團隊一路走來的歷程：從最初的實驗探索，到如今的系統(tǒng)化藥物發(fā)現(xiàn)平臺，他說，這是一段由好奇心驅(qū)動、以團隊協(xié)作為基石，并秉承初心推動科學(xué)進步的旅程。

讓技術(shù)回歸初衷

在2018年以前，DNA編碼化合物庫技術(shù)還是一項始于學(xué)術(shù)界的前沿科技：通過給每個小分子連接獨特的DNA標(biāo)簽，科學(xué)家們可以同時篩選數(shù)百萬甚至數(shù)十億個化合物。這項創(chuàng)新突破對于行業(yè)而言極具顛覆性，能夠顯著提升藥物發(fā)現(xiàn)的效率，但在實際應(yīng)用中，由于技術(shù)門檻高、成本昂貴，只有少數(shù)頂尖實驗室才能駕馭。

“DEL最初的理念，其實是幫助資源有限的小型實驗室更高效地開展藥物發(fā)現(xiàn)，”蒯樂天博士解釋道，“但發(fā)展過程中，它卻逐漸演變?yōu)橐环N高成本、高度集中的服務(wù)模式，反而背離了原本的初衷。”

加入藥明康德生物學(xué)平臺后，他的目標(biāo)清晰而堅定：讓DEL技術(shù)回歸初心——開放、普惠，成為每一位科研人員都能輕松使用的工具。

如同初創(chuàng)企業(yè)一般，團隊以敏捷的方式起步：精簡高效，快速試錯，持續(xù)迭代。僅用六個月，他們便開發(fā)出首個DEL產(chǎn)品的篩選原型；一年后，迎來了第一位客戶。“當(dāng)我們正式推出DEL篩選服務(wù)時，反響遠超預(yù)期，”蒯樂天博士回憶道。那位早期客戶后來成功推進項目并實現(xiàn)上市，驗證了這項技術(shù)的實用價值與應(yīng)用潛力。

此后，在藥明康德平臺上，DEL不再只是實驗室里的前沿概念，而是真正轉(zhuǎn)化為穩(wěn)定、可靠的實用工具。隨著DELopen、DELight、DELpro等系列產(chǎn)品的推出，藥明康德DEL服務(wù)的行業(yè)關(guān)注度迅速提升，“回頭客”也越來越多。此后，基于WuXi Biology DEL服務(wù)的研究成果陸續(xù)發(fā)表，口碑在科研圈中口口相傳。這項技術(shù)從最初的探索性嘗試，逐步成長為行業(yè)想要快速發(fā)現(xiàn)新藥候選分子的優(yōu)選。

“我們的成功離不開公司自上而下給予的支持與信任，”蒯樂天博士感慨道，“在DEL發(fā)展的最初階段，公司給予了我們充分的探索空間和成長耐心，這種信任極為珍貴。”

DEL技術(shù)的產(chǎn)品化突破不僅體現(xiàn)在技術(shù)層面，更是一場思維方式的革新。“我們的目標(biāo)是把DEL做得足夠簡單——無論你是化學(xué)家還是生物學(xué)家，無論來自初創(chuàng)公司還是大型藥企，都能像使用常規(guī)實驗工具一樣輕松上手。”

產(chǎn)品化的精髓在于用戶的自主使用。為此，WuXi Biology團隊做出了很多努力，讓DEL的流程標(biāo)準(zhǔn)化，并內(nèi)置多重質(zhì)量控制機制，確保不同經(jīng)驗水平的科研人員都能獲得可靠結(jié)果。“在內(nèi)測階段，我們邀請了許多從沒做過DEL的化學(xué)背景的同事，按照操作手冊一步步親自操作篩選實驗，最終證明效果非常好。”蒯樂天博士笑著說。

正是那一刻，他真切意識到：團隊已經(jīng)成功將原本復(fù)雜艱深的篩選服務(wù)，轉(zhuǎn)變?yōu)榱鞒毯喢鳌⒓撮_即用的科研產(chǎn)品——科學(xué)，真正變得觸手可及。

為客戶定制最優(yōu)的方案

從最初的小規(guī)模應(yīng)用，到如今影響產(chǎn)業(yè)界，DEL為新藥發(fā)現(xiàn)的范式帶來了深入人心的改變。WuXi Biology DEL技術(shù)，也從一項探索性工具發(fā)展為賦能全球客戶研發(fā)創(chuàng)新的引擎。

如今，WuXi Biology的DEL平臺每年為客戶執(zhí)行數(shù)百次篩選，測試數(shù)十億級別的化合物，廣泛覆蓋癌癥、神經(jīng)科學(xué)等多個前沿領(lǐng)域。

更超越預(yù)期的是，DEL不再只是眾多篩選手段之一，而是成為WuXi Biology整個藥物發(fā)現(xiàn)體系的基石。在短短數(shù)年間，客戶對DEL的篩選的選用量已趕超甚至超過其他傳統(tǒng)平臺的總和，重塑了新藥發(fā)現(xiàn)的科研方法與機制。

“當(dāng)DEL真正起飛時，”蒯樂天博士表示，“我們不只是擴展了一項技術(shù)服務(wù)，而是重構(gòu)了整個早期發(fā)現(xiàn)的流程。”

為了進一步助力行業(yè)提升早期藥物發(fā)現(xiàn)的成功率，WuXi Biology將DEL與片段篩選（Fragment Screening）、高通量篩選（HTS）等技術(shù)深度融合，打造了一個多維協(xié)同的綜合發(fā)現(xiàn)平臺。如今，面對客戶需求，團隊不再局限于“用哪種技術(shù)”，而是回歸本質(zhì)：“你要解決什么科學(xué)問題？”——基于此，為客戶量身定制最優(yōu)的技術(shù)組合方案。“我們提供的是系統(tǒng)性的解決方案，而非孤立的服務(wù)模塊。”蒯樂天博士強調(diào)。如今，除了小分子發(fā)現(xiàn)之外，DEL平臺還可以提供噬菌體、mRNA和多肽的篩選服務(wù)。

目前進行早期藥物發(fā)現(xiàn)的客戶中，許多是充滿活力的初創(chuàng)生物技術(shù)公司。它們其中有些團隊僅有兩位科學(xué)家，但是擁有顛覆性的治療構(gòu)想。“下一個重大突破，很可能就來自這樣的小團隊。”他說道。

然而，這些新興企業(yè)往往面臨融資壓力大、時間窗口緊、資源有限等現(xiàn)實挑戰(zhàn)。蒯樂天博士回憶起一次數(shù)年前的合作。當(dāng)時，一家初創(chuàng)生物公司僅有四個月時間窗口，必須在融資前獲得具有活性的先導(dǎo)化合物數(shù)據(jù)。若無法按時交付，項目可能被迫終止。蒯樂天博士帶領(lǐng)團隊全力推進，在短短兩個月內(nèi)幫助客戶完成了DEL篩選并交付高質(zhì)量結(jié)果，助力這家公司成功獲得1000萬美元新一輪融資。

“客戶說，我們讓他們逃過了‘死亡之谷’，得以繼續(xù)前行。”蒯樂天博士感慨道，“我們由衷為客戶感到高興，同時也深深感受到了‘藥明速度’的對于客戶和行業(yè)的價值所在。”

更可貴的是，當(dāng)WuXi Biology的平臺深度融入藥明康德全球CRDMO網(wǎng)絡(luò)，一體化的平臺優(yōu)勢更加凸顯。一個分子從DEL篩選起步后，可在全球范圍內(nèi)無縫流轉(zhuǎn)：比如它可以在歐洲完成靶點驗證，在亞洲實現(xiàn)化合物合成，在北美推進優(yōu)化與開發(fā)。

“這就是我們‘跟隨分子’（Follow-the-Molecule）戰(zhàn)略的魅力所在，”蒯樂天博士說，“客戶無需在每個研發(fā)階段重新搭建團隊或轉(zhuǎn)移技術(shù)，藥明康德可以陪伴他們走完從概念到上市的全旅程。”

這樣的合作正在藥明康德平臺上出現(xiàn)。在一所大學(xué)研究團隊的早期探索項目中，客戶的學(xué)術(shù)團隊提出一個全新靶點假設(shè)，WuXi Biology通過DEL篩選，快速幫助客戶鎖定苗頭化合物；此后，這個項目一直在藥明康德平臺上向下游流轉(zhuǎn)，完成后續(xù)的化合物合成、結(jié)構(gòu)優(yōu)化與生物學(xué)驗證。

“這正是學(xué)術(shù)界與工業(yè)界高效協(xié)同的理想模式——開放、聚焦、無縫銜接。”蒯樂天博士評價道，“它證明了，當(dāng)我們把復(fù)雜技術(shù)變得簡單可用時，真正的創(chuàng)新才能加速發(fā)生。”

既是科學(xué)家，也是夢想家

盡管身為藥明康德副總裁，生物學(xué)業(yè)務(wù)平臺首席科學(xué)官，蒯樂天博士有時也會將自己定位為一名“打造科學(xué)工具的工程師”。他的理想不僅限于推動科學(xué)進步，更在于重塑科學(xué)本身——讓藥物發(fā)現(xiàn)走向可規(guī)模化、可重復(fù)的工業(yè)體系。

“我夢想中的科學(xué)，是像現(xiàn)代工廠一樣，每一步都可靠、可預(yù)測、可優(yōu)化。”他說，“但工業(yè)化并不意味著削弱科學(xué)本身的創(chuàng)造力。恰恰相反，工業(yè)化能釋放科學(xué)家的想象力，讓好的想法更快落地，并最終惠及更多患者。”

在這樣理念的驅(qū)動下，WuXi Biology持續(xù)構(gòu)建高效、普惠的綜合發(fā)現(xiàn)平臺，致力于將“藥明速度”轉(zhuǎn)化為“藥明范式”——一個以客戶問題為導(dǎo)向、技術(shù)深度融合、流程高度標(biāo)準(zhǔn)化的新一代藥物研發(fā)引擎。

如今，WuXi Biology平臺能夠全面支持多種前沿藥物類型，涵蓋共價抑制劑、雙功能結(jié)合劑、分子膠、PROTAC?（蛋白降解靶向嵌合體）、肽類以及寡核苷酸等復(fù)雜分子形式。團隊不僅提供篩選服務(wù)，更配套開發(fā)了面向新分子的DEL庫和先進的研究系統(tǒng)，助力科學(xué)家探索傳統(tǒng)方法難以觸及的化學(xué)空間與生物學(xué)機制。

“早在五年前，我們就前瞻性地布局了降解劑、偶聯(lián)物等新分子類型的化合物庫的建設(shè)，”蒯樂天博士回憶道，“當(dāng)時這些還屬于小眾領(lǐng)域，但今天我們看到，它們已成為客戶最常使用的服務(wù)之一。我們不是在追趕趨勢，而是在趨勢形成前就已準(zhǔn)備就緒。”

產(chǎn)業(yè)正在將目光投向更具挑戰(zhàn)性的疾病領(lǐng)域：腦部疾病、自身免疫疾病、代謝性疾病……這些疾病的靶點往往更復(fù)雜、通路更模糊、數(shù)據(jù)維度更高。“下一輪藥物發(fā)現(xiàn)的技術(shù)革命，要‘更快’、‘更聰明’。”他強調(diào)，“我們需要更強的數(shù)據(jù)解析能力、更靈活的技術(shù)組合，以及更深的跨學(xué)科協(xié)作。”

他堅信，未來的突破將由新一代分子定義——如多靶點配體、抗體偶聯(lián)藥物（ADC）、功能性寡核苷酸等。“我們正在并將繼續(xù)構(gòu)建能夠讓科學(xué)家從項目早期就能有效處理這些復(fù)雜分子的工具鏈，無論是設(shè)計、篩選還是優(yōu)化。”

正是這種前瞻性的技術(shù)儲備與系統(tǒng)化的服務(wù)能力，使得全球客戶高度信賴WuXi Biology的洞察力。“每年，我們與數(shù)千名來自全球的創(chuàng)新者合作，接觸海量的真實研發(fā)需求，”蒯樂天博士說，“這讓我們有機會更早感知到下一波浪潮的方向。”

在他看來，真正的創(chuàng)新不僅是解決今天的問題，更是為明天的挑戰(zhàn)鋪路。“我們既是科學(xué)家，也是夢想家。而我們的使命，就是讓夢想中的療法，在現(xiàn)實世界中加速誕生。”

看到遙遠的未來

盡管蒯樂天博士的對話中常出現(xiàn)“系統(tǒng)”“數(shù)據(jù)”“通量”等技術(shù)詞匯，但驅(qū)動他前行的，始終是一份深沉的人文情懷。

他從未忘記自己作為一名科研工作者的初心——相信每一個科學(xué)構(gòu)想都值得被認(rèn)真對待，每一個微小的突破背后，都可能承載著患者對生命的期盼。

“每一個項目、每一次實驗，都不只是一個化合物或一組數(shù)據(jù)，”蒯樂天博士說，“它往往是一個科學(xué)家的夢想，一個團隊的堅持，甚至是一個家庭的希望。我們的職責(zé)，就是通過強大的賦能平臺能力，讓這些想法有機會真正轉(zhuǎn)化為治病救人的藥物。”

展望未來，蒯樂天博士對WuXi Biology的科學(xué)發(fā)展有著清晰而充滿想象力的期待：打造一個持續(xù)進化的新一代藥物發(fā)現(xiàn)平臺，深度融合計算科學(xué)、合成化學(xué)與現(xiàn)代生物學(xué)，形成自我迭代的技術(shù)生態(tài)。它將以速度為驅(qū)動、以信任為基石、以好奇心為動力。

在他心中，藥明康德“讓天下沒有難做的藥，難治的病”的愿景，更像是一個科學(xué)理想。

“它意味著我們必須始終保持開放的心態(tài)，敢于打破邊界，勇于從零開始學(xué)習(xí)和創(chuàng)造。”蒯樂天博士說，“科學(xué)的本質(zhì)就是不斷重構(gòu)、不斷超越。而我們能做的，就是搭建一個足夠強大、足夠靈活的平臺，讓全球的創(chuàng)新者都能站上這個舞臺，加速實現(xiàn)他們的新藥研發(fā)夢想。這是我們對科學(xué)理想的追求，也是推動我們不斷前進的力量。”

“未來已來，”蒯樂天博士微笑道，“而我們，正站在新藥發(fā)現(xiàn)的下一個起點。”

Building a Tool to Democratize Discovery

Editor’s Note: “Every drug can be made and every disease can be treated”. Over the past 25 years, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision.

In tribute to the journey and in celebration of new beginnings, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

When Dr. Letian Kuai walked onto the stage at WuXi AppTec’s 25th Anniversary Ceremony to receive the Distinguished Scientist Award, the room filled with proud applause.

The recognition wasn’t only for his scientific skills. It was for his team’s vision, which changed how new medicines can be discovered.

Seven years earlier, Kuai had joined WuXi Biology with little more than an idea: to turn DNA-encoded library (DEL) screening, once a complex, academic experiment, into a practical tool that any scientist could use.

“We started from zero,” he recalls. “No equipment, no handbook, just the belief that we could build something that would change how people find new drugs.”

That belief soon became reality. Today,DEL is WuXi Biology’s fastest-growing platform, screening billions of compounds for its clients each year and enabling thousands of scientists around the world.

As Kuai stood under the lights that night, he could look back on how far his team had come, from a few early experiments to a system that now speeds up discovery across the globe. It was a journey, he says, powered by curiosity, teamwork, and the art of building tools that help science move faster.

Turning Science into an Accessible Tool

Before 2018, DEL technology was a new concept. Scientists could attach a DNA tag to each small molecule, allowing them to test millions of compounds at the same time. It sounded revolutionary, but in practice only a few advanced labs had access to use it.

“When DEL first appeared, it was meant to help small labs,” Kuai explains. “But over time, it turned into an expensive, exclusive service. That went against its original purpose.”

Kuai wanted to change that. When he joined WuXi Biology, he dreamed of bringing DEL back to its roots: making discovery open and accessible to everyone.

He started with a tiny team, working like a startup: building, testing, and improving every step of the way. Six months later, they developed their first screening tool. A year later, they welcomed their first client. “When we launched the screening service, it was an instant success,” Kuai says. That first client later went public, a sign that our early efforts truly made an impact.

That was the turning point.DEL was no longer a niche technology—it had become a practical, reliable tool.The industry quickly took notice. Clients kept returning, publishing high-quality research using WuXi Biology’s DEL services, and recommending the service to others. What began as a small experiment had grown into something that changed how discovery could happen.

“I believe our success came from WuXi AppTec’s strong support and trust,” Kuai adds. “During the earliest stage of DEL development, the company gave us the freedom to explore and the patience to grow.”

Their breakthrough wasn’t only about science: it was about mindset. “Our goal,” he says, “was to make DEL simple enough that any scientist—chemist or biologist, startup or large pharma—could use it easily.”

At WuXi Biology, the team focused on standardizing their process and adding built-in safety features so that scientists of any experience level could succeed. They even invited chemists to follow the biologists’ instructions and try DEL themselves. “We invited our chemists to try DEL using the biologists’ protocols. They followed the instructions and ran the screening themselves, and it worked beautifully.” Kuai laughs.

That was the moment that he realized his team successfully redesigned DEL from a complicated screening service into a bullet-proof, ready-to-use product.

From One Library to a Global Platform

What began as a small experiment later changed how scientists discover new medicines. Today, WuXi Biology’s DEL platform hundreds of screenings each year, testing billions of compounds for its clients. The projects cover many fields, from cancer research to neuroscience.

DEL is no longer just one of many tools. It has become the foundation of WuXi Biology’s discovery work. Within only a few years, its client usage surpassed all the other screening platforms combined within WuXi Biology, completely transforming how new molecules are discovered.

“Once DEL took off,” Kuai says, “we didn’t just expand one service, we changed the process of early discovery.”

WuXi Biology then combined DEL with other methods such as fragment screening and high-throughput screening, creating a powerful, all-in-one platform that helps clients find complete solutions instead of single services.“We no longer start by asking what technology to use,” Kuai explains. “We start by asking what problem the client wants to solve, and then we design the best plan around it.” Beyond small molecule discovery, the platform now offers phage display, mRNA display for peptides as well.

Most of WuXi Biology’s clients are small startups. Some are just two scientists with a bold idea. “The next big breakthrough could come from them,” Kuai says. But these young companies often face tight deadlines and difficult targets.

He recalls one biotech company that came to his team during a critical moment. They had only four months to raise new funding, and success depended on finding promising compounds quickly. Kuai’s team delivered results in just two months. Those findings helped the company raise ten million dollars and continue its research. “They told us we made the difference between running out of time and moving forward,” Kuai says. “That’s what WuXi Speed means in real life.”

The platform is now deeply connected across WuXi AppTec’s global CRDMO network. A project that begins with Kuai’s team can continue seamlessly through every next step: target validated in Europe, compound synthesized in Asia, and optimization in North America. “That’s the beauty of our ‘Follow the Molecule’ strategy,” Kuai says. “Clients don’t have to start over at each stage. We stay with them through the entire journey.”

One of his favorite examples is a collaboration with a university research group. The scientists explored early targets, and WuXi Biology supported them with DEL screening. Later, the program stayed at WuXi AppTec’s platform for compound synthesis and validation. “It became a perfect example of how academia and our integrated service can work together,” Kuai says. “Fast, focused, and open.”

A Scientist Who Engineers Tools

Even though Kuai is the Vice President, Chief Scientific Officer of WuXi Biology, he still sees himself first and foremost as an engineer of tools. His dream now is to make scientific discovery work with the same reliability and precision as a factory, where every process can be repeated and improved.

“Industrialization doesn’t make science less creative,” he says. “It helps ideas grow and reach more people.”His goal is to turn discovery into a system that works faster, smarter, and more reliably. “That’s how we bring new treatments to patients sooner,” he adds. “That’s what WuXi Speed is all about—when innovation becomes part of the foundation.”

Today, this integrated platform is one of WuXi Biology’s greatest strengths. It supports a wide range of modern drug types, from covalent and bifunctional binders to molecular glues, PROTAC?s, peptides, and oligonucleotides. His team has also created new DEL libraries and advanced research systems that allow scientists to explore new areas of chemistry.

“Five years ago, we started building libraries for new drug types such as degraders and conjugates,” Kuai says. “Now, those are some of our most requested tools. We were ready before the trend began.”

When asked what he’s focused on next, Kuai’s answer blends science and strategy. “We are seeing more work on complex diseases such as brain disorders, immune diseases, and metabolic conditions,” he says. “The science is more difficult, and the data is more complicated. The next revolution will not only be faster discovery, but smarter discovery.”

He believes the future will be defined by new kinds of molecules, including oligonucleotides, multi-target ligands, and antibody drug conjugates. “We have built and will continue to develop the tools to help scientists working with them from the very beginning,” he says.

That ability to sense the next big wave before it happens is something clients have come to depend on. “We work with thousands of scientists every year,” Kuai says. “Sometimes, we can see the next big wave coming even before the industry realizes it.”

The Vision Ahead

Even though Kuai often talks about systems and data, his motivation is deeply human. He still thinks like a scientist who believes that every idea deserves a chance.

“Every project and every experiment carries someone’s hope,” he says. “Our job is to give those hopes a real chance to become medicines.”

As WuXi AppTec looks toward the next 25 years, Kuai’s vision for WuXi Biology is clear. He wants to build a constantly evolving discovery platform that brings together computing, chemistry, and biology. It will be powered by speed, built on trust, and driven by curiosity.

“To me,” he says, “our mission that ‘every drug can be made and every disease can be treated’ means staying open-minded, ready to learn, to create, and to begin again. That’s what science is all about. That’s what keeps us moving forward.”

免責(zé)聲明：本文 僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療 方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請在「藥明康德」微信公眾號回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。